<DOC>
	<DOC>NCT00043394</DOC>
	<brief_summary>To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients with metastatic breast cancer.</brief_summary>
	<brief_title>CPG 7909 Plus Herceptin速 In Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirmed breast cancer with metastases Tumor that has overexpression of HER2 as documented by being either FISHpositive or HER2/neu 3+ confirmed by immunohistochemistry Patients may have had up to three prior chemotherapy regimens for metastatic disease, which may have been given in combination with Herceptin速 and which may have been discontinued due to toxicities. In addition, patients may have had adjuvant chemotherapy. Phase II only: Must have measurable disease by RECIST criteria (defined in section 8) with at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as &gt; 20 mm with conventional techniques, or as &gt; 10 mm with spiral CT scan Any prior therapy with anthracycline + Herceptin速 concurrently Significant cardiovascular disease (e.g., NYHA class 3 congestive heart failure, myocardial infarction within the past 6 months, unstable angina; coronary angioplasty within the past 6 months, uncontrolled atrial or ventricular cardiac arrhythmias) or left ventricular ejection fraction &lt; 50% Preexisting autoimmune or antibodymediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>CpG 7909 subcutaneous injection combination with Herceptin速 metastatic breast cancer.</keyword>
</DOC>